Sign Out
Pregnancy: For escitalopram, only limited clinical data are available regarding exposed pregnancies. In reproductive toxicity studies performed in rats with escitalopram, embryo-fetotoxic effects, but no increased incidence of malformations, were observed (see Pharmacology: Toxicology: Preclinical Safety Data under Actions). Escitalopram should not be used during pregnancy unless clearly necessary and only after careful consideration of the risk/benefit.
Neonates should be observed if maternal use of escitalopram continues into the later stages of pregnancy, particularly in the third trimester. Abrupt discontinuation should be avoided during pregnancy.
The following symptoms may occur in the neonate after maternal SSRI/SNRI use in later stages of pregnancy: Respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either serotonergic effects or discontinuation symptoms.
In a majority of instances the complications begin immediately or soon (<24 hours) after delivery.
Epidemiological data have suggested that the use of SSRIs in pregnancy, particular in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1,000 pregnancies. In the general population 1 to 2 cases of PPHN per 1,000 pregnancies occur.
Breastfeeding: It is expected that escitalopram will be excreted into human milk.
Consequently, breast-feeding is not recommended during treatment.
Fertility: Animal data have shown that citalopram may affect sperm quality (see Pharmacology: Toxicology: Preclinical Safety Data under Actions). Human case reports with some SSRIs have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed so far.
